Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261220 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 380
- Enrollment target
NCT02261220: Completed Phase 1 study, sponsored by MedImmune.
NCT02261220 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 380 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (533% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02261220, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 380 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
Interventions
- BIOLOGICAL MEDI4736
- BIOLOGICAL tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2020-01-27 |
| Phase | Phase 1 |
What the finished NCT02261220 record still lists
NCT02261220 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (533% higher).
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 is the first listed.
NCT02261220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02261220 about?
NCT02261220 is a clinical study titled "A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors". This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
What is the current status of trial NCT02261220?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2014-10-13. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT02261220?
The interventions under investigation include: MEDI4736 (BIOLOGICAL), tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02261220?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02261220's enrollment target sits among peer trials
380 81st of 2000 higher than 1,917 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI